Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) have earned an average rating of "Moderate Buy" from the eleven ratings firms that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation and nine have assigned a...